Medindia LOGIN REGISTER
Medindia
Advertisement

Spruce Biosciences Announces Positive Results from 12-week, Phase 2a Study of Tildacerfont in Adults with Congenital Adrenal Hyperplasia

Thursday, September 19, 2019 General News
Advertisement
- Tildacerfont demonstrated maximum mean reductions of 84% adrenocorticotropic hormone (ACTH), 82% 17-hydroxyprogesterone (17-OHP) and 79% androstenedione (A4), key disease biomarkers in CAH patients with elevated androgens

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close